JP7695891B2 - ジスキネジア治療薬 - Google Patents

ジスキネジア治療薬 Download PDF

Info

Publication number
JP7695891B2
JP7695891B2 JP2021561833A JP2021561833A JP7695891B2 JP 7695891 B2 JP7695891 B2 JP 7695891B2 JP 2021561833 A JP2021561833 A JP 2021561833A JP 2021561833 A JP2021561833 A JP 2021561833A JP 7695891 B2 JP7695891 B2 JP 7695891B2
Authority
JP
Japan
Prior art keywords
tandospirone
levodopa
dyskinesia
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021561833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529661A (ja
Inventor
光將 栗田
友紀 池田
充宏 中塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of JP2022529661A publication Critical patent/JP2022529661A/ja
Priority to JP2025017181A priority Critical patent/JP2025072496A/ja
Application granted granted Critical
Publication of JP7695891B2 publication Critical patent/JP7695891B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021561833A 2019-04-26 2020-04-24 ジスキネジア治療薬 Active JP7695891B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025017181A JP2025072496A (ja) 2019-04-26 2025-02-04 ジスキネジア治療薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/395,531 2019-04-26
US16/395,531 US10758535B1 (en) 2019-04-26 2019-04-26 Therapeutic drug for dyskinesia
PCT/JP2020/017652 WO2020218487A1 (en) 2019-04-26 2020-04-24 Therapeutic drug for dyskinesia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025017181A Division JP2025072496A (ja) 2019-04-26 2025-02-04 ジスキネジア治療薬

Publications (2)

Publication Number Publication Date
JP2022529661A JP2022529661A (ja) 2022-06-23
JP7695891B2 true JP7695891B2 (ja) 2025-06-19

Family

ID=72241591

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021561833A Active JP7695891B2 (ja) 2019-04-26 2020-04-24 ジスキネジア治療薬
JP2025017181A Pending JP2025072496A (ja) 2019-04-26 2025-02-04 ジスキネジア治療薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025017181A Pending JP2025072496A (ja) 2019-04-26 2025-02-04 ジスキネジア治療薬

Country Status (13)

Country Link
US (3) US10758535B1 (enExample)
EP (1) EP3958972A4 (enExample)
JP (2) JP7695891B2 (enExample)
KR (1) KR20220004640A (enExample)
CN (1) CN113646045A (enExample)
AU (1) AU2020260895A1 (enExample)
BR (1) BR112021021184A8 (enExample)
CA (1) CA3137400A1 (enExample)
EA (1) EA202192928A1 (enExample)
MX (1) MX2021013070A (enExample)
PH (1) PH12021552681A1 (enExample)
SG (1) SG11202111852TA (enExample)
WO (1) WO2020218487A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11559525B2 (en) * 2019-04-26 2023-01-24 Sumitomo Pharma Co., Ltd. Therapeutic drug for dyskinesia
CA3168199A1 (en) 2020-02-19 2021-08-26 Eri ICHIBAYASHI Transdermal absorption preparation
JPWO2022045336A1 (enExample) * 2020-08-31 2022-03-03
CA3221728A1 (en) * 2021-06-30 2023-01-05 Grace S. LIANG Valbenazine for use in the treatment of dyskinesia due to cerebral palsy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060193900A1 (en) 2005-02-28 2006-08-31 Hisamitsu Pharmaceutical Co., Inc. Pressure sensitive adhesive and patch
WO2013156035A1 (en) 2012-04-18 2013-10-24 Concit Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507303A (en) 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
JPH11228414A (ja) 1998-02-06 1999-08-24 Sumitomo Pharmaceut Co Ltd タンドスピロン経皮剤
ES2716404T3 (es) * 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
WO2005117886A1 (ja) 2004-06-01 2005-12-15 Hisamitsu Pharmaceutical Co., Inc. 貼付剤
ATE413166T1 (de) 2004-11-22 2008-11-15 Hisamitsu Pharmaceutical Co Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff
WO2008044336A1 (en) 2006-10-11 2008-04-17 Hisamitsu Pharmaceutical Co., Inc. Crystal-containing adhesive preparation
EP2729176A1 (en) 2011-07-05 2014-05-14 Contera Pharma APS The use of serotonin receptor agonists for treatment of movement disorders
EP3897641B1 (en) * 2018-12-20 2023-11-15 Contera Pharma A/S Treatment of movement disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060193900A1 (en) 2005-02-28 2006-08-31 Hisamitsu Pharmaceutical Co., Inc. Pressure sensitive adhesive and patch
WO2013156035A1 (en) 2012-04-18 2013-10-24 Concit Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders

Also Published As

Publication number Publication date
WO2020218487A1 (en) 2020-10-29
EP3958972A1 (en) 2022-03-02
KR20220004640A (ko) 2022-01-11
MX2021013070A (es) 2021-11-17
EP3958972A4 (en) 2023-01-04
AU2020260895A1 (en) 2021-12-23
JP2022529661A (ja) 2022-06-23
EA202192928A1 (ru) 2022-02-07
SG11202111852TA (en) 2021-11-29
CA3137400A1 (en) 2020-10-29
BR112021021184A2 (enExample) 2021-12-14
US20220193075A1 (en) 2022-06-23
US20210060015A1 (en) 2021-03-04
US10758535B1 (en) 2020-09-01
JP2025072496A (ja) 2025-05-09
BR112021021184A8 (pt) 2023-02-28
CN113646045A (zh) 2021-11-12
PH12021552681A1 (en) 2022-09-19

Similar Documents

Publication Publication Date Title
JP2025072496A (ja) ジスキネジア治療薬
CN107405347B (zh) 用于治疗处理或美容处理过量体脂肪的nk-3受体拮抗剂
CN101543497A (zh) 治疗运动疾病患者的方法
WO2014037416A2 (en) New therapeutic approaches for treating parkinson's disease
JP6634445B2 (ja) ブスピロン代謝産物の使用
US20230241062A1 (en) Therapeutic drug for motor complications in parkinson's disease
AU2007259256A1 (en) Combination preparations comprising bifeprunox and L-DOPA
KR20070029740A (ko) 통증 치료를 위한 레복세틴의 용도
US20230201199A1 (en) Therapeutic drug for dyskinesia
JP2006508118A5 (enExample)
EA046505B1 (ru) Терапевтическое лекарственное средство для лечения дискинезии
JPH09500375A (ja) パーキンソン病の治療を目的とする医薬品の製造のためのエファロキサンおよびその誘導体の使用
CA2654719A1 (en) Combination preparations comprising slv308 and a l-dopa
US8106056B2 (en) Combination preparations comprising bifeprunox and a dopamine agonist
JP2023082771A (ja) パーキンソン病治療薬
JP2020033322A (ja) パーキンソン病の治療のための医薬組成物
HK1135017A (en) Combination preparations comprising slv308 and a l-dopa
HK1130677A (en) Combination preparations comprising bifeprunox and l-dopa
MX2008016226A (es) Preparaciones de combinacion que comprenden bifeprunox y l-dopa.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230403

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230728

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250609

R150 Certificate of patent or registration of utility model

Ref document number: 7695891

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150